- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Anne Barmettler on Barriers Stymying Provider Uptake of Teprotumumab
Anne Barmettler, MD, an associate professor of ophthalmology, visual sciences, and plastic surgery at Montefiore Medical Center, discusses the cost of teprotumumab for thyroid eye disease.
Although teprotumumab is the first treatment for thyroid eye disease to gain FDA approval, its cost has served as a barrier to treatment uptake by providers, said Anne Barmettler, MD, an associate professor of ophthalmology, visual sciences, and plastic surgery at Montefiore Medical Center.
Transcript
How has provider uptake of teprotumumab been since the drug's approval?
Teprotumumab is very exciting for both doctors and patients because it is the first drug available for thyroid eye disease. The issue with it is that it is extremely expensive, and it isn't just a medication that you can take easily. It's an infusion that has to be done every 3 weeks for 24 weeks. So it's a commitment and you need to have a way of getting that infusion into the patient. So that, plus the cost of the medication and monitoring for side effects has made it a little bit tougher for everyone to get this into their practice.
Has the steep price tag of teprotumumab stymied uptake?
Yes, the answer is definitely yes. So, for an average-sized adult the price tag is around $300,000 per person. Understandably, insurance companies are really hesitant to pay for this because they could treat a lot of other people with that same amount of money. So there have been a number of issues in place with insurance companies not wanting to cover this medication unless other treatments have been tried and failed, or certain exam criteria have been met and documented. Those are definitely things that are slowing down its use.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
The Federal Trade Commission's (FTC's) vote to ban most employers from issuing and enforcing noncompete clauses could have varying impacts on the health care workforce; federal regulators vastly under-enforced antitrust laws in the hospital sector during the last 2 decades, resulting in increased health costs; the FDA recently found genetic evidence of the H5N1 bird flu virus in pasteurized commercially purchased milk.
Read More
